LAB International completes patient enrollment in Fentanyl Taifun trial

By Elaine Rigoli

Tampa, Fla., April 3 - LAB International, Inc. has completed patient enrollment for the phase 2a trial of its lead product, Fentanyl Taifun, enrolling 122 cancer patients on maintenance opioid therapy for persistent pain.

The multi-center, randomized, double-blind, placebo-controlled trial is investigating the efficacy and safety of Fentanyl Taifun for the treatment of breakthrough cancer pain, monitoring response at different Fentanyl doses, according to a news release.

Recently published results from a comparative phase 1 study demonstrated exceptionally rapid absorption after a single inhalation of Fentanyl Taifun 200 (micro) g, the release said.

Chronic pain associated with advanced cancer is commonly treated with strong opioid analgesics, such as Fentanyl. Break-through pain episodes are common in cancer patients, often occurring several times a day.

In accordance to previously disclosed timelines, the company said it expects to have results from the study available in June.

LAB International is a drug-development company focused on the inhalation market and is based in Laval, Quebec.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.